Rationale, current state and opportunities in combining biologic disease modifying antirheumatic drugs in rheumatoid and psoriatic arthritis.
Biologicals
Combination therapy
Cytokine blockade
Psoriatic arthritis
Rheumatoid arthritis
Journal
Joint bone spine
ISSN: 1778-7254
Titre abrégé: Joint Bone Spine
Pays: France
ID NLM: 100938016
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
27
11
2022
revised:
23
03
2023
accepted:
29
03
2023
medline:
29
9
2023
pubmed:
20
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
The advent of biologic disease modifying antirheumatic drugs (bDMARDs) has considerably improved patient outcomes in inflammatory arthritis. However, not all patients reach the state of remission, as disease can be resistant even to single cytokine inhibition by bDMARDs. Simultaneous or sequential inhibition of multiple cytokines may be considered in situations where disease control is not adequate under singular inhibition of cytokines. Although there have been some disappointing experiences in the past with combination of bDMARDs, the ongoing improvement of our understanding about inflammatory pathways and the overall better safety understanding of bDMARDs seem to make new biologic treatment combinations possible. This review covers the rationale and current evidence for bDMARDs combination in inflammatory arthritis.
Identifiants
pubmed: 37076093
pii: S1297-319X(23)00057-X
doi: 10.1016/j.jbspin.2023.105578
pii:
doi:
Substances chimiques
Antirheumatic Agents
0
Cytokines
0
Biological Products
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105578Informations de copyright
Copyright © 2023. Published by Elsevier Masson SAS.